Akari Therapeutics Plc - Form 6-K Summary
Business Context and Reporting Period
This Form 6-K report covers the month of June 2023 for Akari Therapeutics Plc, a public company incorporated under the laws of England and Wales. The filing documents the outcomes of the Annual General Meeting of Shareholders held on June 30, 2023.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and does not contain financial statements or performance metrics.
Material Changes
The primary material change reported is a shift in the Company's Board of Directors. While all proposals brought before shareholders were approved, the specific proposals for the election of David Byrne, James Hill, and Stuart Ungar to the Board were not approved. Consequently, the tenures of Dr. Hill, Mr. Byrne, and Dr. Ungar ended at the conclusion of the meeting.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, specific risks, contingencies, or unusual items. The document serves as a notification of the shareholder meeting results and incorporates by reference the Notice of Annual General Meeting and Proxy Statement filed on June 6, 2023.
Key Facts for Investor Verification
- Three directors (David Byrne, James Hill, and Stuart Ungar) were not re-elected to the Board of Directors at the June 30, 2023 meeting.
- All other proposals presented to shareholders were approved.
- Detailed information regarding the director elections is contained in the Proxy Statement dated June 6, 2023 (Exhibit 99.2).
- This filing contains no financial performance data for the period.